Animal study · rats
ARA-290 eased nerve-injury pain for up to 20 weeks in rats
Checked against the paper Animal studyPublished by PepVault
The takeaway
In rats, a short early course of ARA-290 after nerve injury was followed by reduced pain responses lasting up to 20 weeks.
- Kind
- Animal study
- Studied in
- Rats
- Published
- 2014
- Journal
- Mol Pain
What they tested
The team tested whether different doses of ARA-290 reduce pain after a nerve injury in rats, and how it affects microglia and astrocytes, immune-type support cells in the spinal cord.
How the study was done
An animal study in rats given a spared nerve injury, treated with vehicle (an inactive carrier) or ARA-290 at 3, 10, 30 or 60 μg/kg on days 1, 3, 6, 8 and 10. Spinal cord tissue was examined at 2 or 20 weeks after injury or sham surgery.

What they found
In rats, ARA-290 lowered mechanical allodynia (pain from light touch) in a dose-related way for up to 20 weeks compared with vehicle. Cold allodynia was also reduced for up to 20 weeks at all four doses. At 2 weeks, vehicle-treated rats showed increased microglia activity in the L5 spinal segment while rats given 10 or 30 μg/kg did not; at 20 weeks only the 30 μg/kg group stayed free of increased microglia activity. Astrocyte reaction did not differ between groups.
What it doesn’t show
Every result comes from rats with a surgical nerve injury, and no people were tested. The calmer spinal microglia and the pain relief were seen together, which hints at a link but does not prove one causes the other.
The paper
Swartjes et al. ARA 290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain coupled with suppression of the spinal microglia response. Mol Pain. 2014.
The compound
More studies on ARA-290
- ARA-290: more corneal nerve fibers at 28 days in sarcoidosis, 4 mg armRandomized trial · people · 2017
- ARA-290 eased neuropathic symptoms in sarcoidosis nerve fiber lossRandomized trial · people · 2013
- ARA-290 improved small fiber neuropathy symptoms in sarcoidosisRandomized trial · people · 2012
- Every study on ARA-290
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.